COMMUNIQUÉS West-GlobeNewswire

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
17/09/2025
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ( [...]
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
17/09/2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome [...]
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
17/09/2025
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE [...]
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
17/09/2025
The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with [...]
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
17/09/2025
Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of [...]
Broken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain “Sprits 26”, Elevates Craft Portfolio with Modern Blue Dream Release
17/09/2025
NANAIMO, British Columbia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading lifestyle and consumer-packaged goods company, announced that its premium craft cannabis [...]
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
17/09/2025
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic reduction in both [...]
TRUE-See Announces Strategic Partnership with Dr. Peter Chang and the Center for Applied AI Research at the University of California, Irvine
17/09/2025
TRUE-See Expands Its AI Clinical Leadership Capabilities with Addition of Dr. Peter Chang as Senior AI Advisor NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- TRUE-See, the leader in AI-driven, color-calibrated medical [...]
Pneumagen Launches NeumoBind™ Technology Platform to Unlock New Opportunities in Intranasal Therapeutics
17/09/2025
Unique technology developed to extend residence time of therapeutic proteins on nasal and other mucosal surfaces Anchoring proteins in place can support enhanced activity Potential to utilise lower dose and reduced [...]
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
17/09/2025
PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT ), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today [...]
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
17/09/2025
Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite selectivity over close homolog, SMARCA4. Rapid, deep and sustained [...]
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
17/09/2025
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong [...]
MyCardiologist Launches Immediate Care Clinic, Offering Same-Day Access to Expert Cardiac Care
17/09/2025
MyCardiologistNow provides a new walk-in clinic for patients needing prompt evaluation of non-life-threatening heart symptoms MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- MyCardiologist , one of South Florida’s leading [...]
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
17/09/2025
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impact on families for [...]
ALK and GenSci partner to expand the AIT market in China
17/09/2025
Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to income from supplying [...]
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
17/09/2025
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal dialysis (PD), today [...]
Oruka Therapeutics Announces $180 Million Private Placement
17/09/2025
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the [...]
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
17/09/2025
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions [...]
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
17/09/2025
Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 to begin in early [...]

Pages